J&J Aims To Convert 5% Of U.S. Spinal Fusion Market To Charité In 2005
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/DePuy will train 2,000 U.S. spine surgeons to implant Charité artificial lumbar discs within the first year of approval, the firm says
You may also be interested in...
Spinal Fusion Device Comparative Trials Deemed Inadequate By TEC
Conflicting results of clinical trials comparing spinal fusion to non-surgical alternatives prompted the BlueCross BlueShield Technology Evaluation Center (TEC) to refrain from endorsing artificial spine disc implantation
J&J Looks To Broaden Spine Offerings, Considers DTC Ads For Charité
Johnson & Johnson is pursuing alternate spinal technologies to address Charité artificial lumbar disc limitations, which are hindering adoption of the device as a stand-alone, total spine treatment
Spinal Fusion Device Comparative Trials Deemed Inadequate By TEC
Conflicting results of clinical trials comparing spinal fusion to non-surgical alternatives prompted the BlueCross BlueShield Technology Evaluation Center (TEC) to refrain from endorsing artificial spine disc implantation